Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

In Vivo Assessment of the Safety of Standard Fractionation Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma: An R-IDEAL Stage 1/2a First-in-Humans/Feasibility Demonstration of New Technology Implementation

Shireen Parsai, Richard Lei J. Qiu, Peng Qi, Geoffrey Sedor, View ORCID ProfileClifton D. Fuller, Eric Murray, David Majkszak, Nicole Dorio, Shlomo Koyfman, Neil Woody, Nikhil Joshi, View ORCID ProfileJacob G. Scott
doi: https://doi.org/10.1101/2021.01.05.21249232
Shireen Parsai
1Department of Radiation Oncology, OhioHealth, Columbus, OH 43214
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Lei J. Qiu
2Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peng Qi
3Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Ave, Cleveland, OH 44195, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey Sedor
4Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifton D. Fuller
5Department of Radiation Oncology, MD Anderson Cancer Center, 1840 Old Spanish Trail, Houston, TX 77054, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Clifton D. Fuller
Eric Murray
3Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Ave, Cleveland, OH 44195, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Majkszak
3Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Ave, Cleveland, OH 44195, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Dorio
3Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Ave, Cleveland, OH 44195, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shlomo Koyfman
3Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Ave, Cleveland, OH 44195, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Woody
3Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Ave, Cleveland, OH 44195, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikhil Joshi
6Department of Radiation Oncology, Rush University, Chicago, IL 60612
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: scottj10@ccf.org dr.nikhil.j@gmail.com
Jacob G. Scott
3Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Ave, Cleveland, OH 44195, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jacob G. Scott
  • For correspondence: scottj10@ccf.org dr.nikhil.j@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Prior in silico simulations of studies of Temporally Feathered Radiation Therapy (TFRT) have demonstrated potential reduction in normal tissue toxicity. This R-IDEAL Stage 1/2A study seeks to demonstrate the first-in-human implementation of TFRT in treating patients with head and neck squamous cell carcinoma (HNSCC).

Materials and Methods Patients with HNSCC treated with definitive radiation therapy were eligible (70 Gy in 35 fractions) were eligible. The primary endpoint was feasibility of TFRT planning as defined by radiation start within 15 days of CT simulation. Secondary endpoints included estimates of acute grade 3-5 toxicity.

Results The study met its accrual goal of 5 patients. TFRT plans were generated in four of the five patients within 15 business days of CT simulation, therefore meeting the primary endpoint. One patient was not treated with TFRT at physician’s discretion, though the TFRT plan had been generated within sufficient time from the CT simulation. For patients who received TFRT, the median time from CT simulation to radiation start was 10 business days (range 8-15). The average time required for radiation planning was 6 days. In all patients receiving TFRT, each subplan and every daily fraction was delivered in the correct sequence without error. The OARs feathered included: oral cavity, each submandibular gland, each parotid gland, supraglottis, and posterior pharyngeal wall (OAR pharynx). Prescription dose PTV coverage (>95%) was ensured in each TFRT subplan and the composite TFRT plan. One of five patients developed an acute grade 3 toxicity.

Conclusions This study demonstrates the first-in-human implementation of TFRT (R-IDEAL Stage 1), proving its feasibility in the modern clinical workflow. Additionally, assessments of acute toxicities and dosimetric comparisons to a standard radiotherapy plan were described (R-IDEAL Stage 2a).

Highlights

  • This prospective study is the first-in-human application for Temporally Feathered Radiation Therapy (TFRT).

  • In theory, TFRT may reduce radiation-induced toxicities by optimizing the time through which radiation is delivered and consequently improve normal tissue recovery.

  • In this study, patients with head and neck squamous cell carcinoma were treated with TFRT.

  • The primary endpoint of technical feasibility was met when patients were successfully treated with TFRT techniques without introducing delays in radiation commencement.

Competing Interest Statement

JGS hold IP on the concept of temporally feathered radiation therapy

Clinical Trial

NCT03768856

Funding Statement

Jacob G Scott: Dr. Scott received funding and salary support from: The National Institutes of Health Paul Calabresi Career Development Award for Clinical Oncology NIH K12CA076917 and MERIT award R37CA244613-01. Clifton D Fuller: Dr. Fuller received funding and salary support from: the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787-01); the National Institute for Dental and Craniofacial Research Establishing Outcome Measures Award (1R01DE025248/R56DE025248) and Academic Industrial Partnership Grant (R01DE028290); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148); an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); an NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Award (P50 CA097007); NIH Big Data to Knowledge (BD2K) Program of the National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825), National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (NSF 1557679); NSF Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant (NSF 1933369); the Stiefel Oropharyngeal Research Fund of the University of Texas MD Anderson Cancer; and the MD Anderson Program in Image-guided Cancer Therapy. Dr. Fuller has received direct industry grant support, in-kind hardware, honoraria, and travel funding from Elekta AB.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

CCF IRB# 18-1248

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Source of Financial Support/ Funding Statement: Research Program Committee (RPC) Grant.

Data Availability

All raw image data are available on request, otherwise they are included.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 06, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
In Vivo Assessment of the Safety of Standard Fractionation Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma: An R-IDEAL Stage 1/2a First-in-Humans/Feasibility Demonstration of New Technology Implementation
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vivo Assessment of the Safety of Standard Fractionation Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma: An R-IDEAL Stage 1/2a First-in-Humans/Feasibility Demonstration of New Technology Implementation
Shireen Parsai, Richard Lei J. Qiu, Peng Qi, Geoffrey Sedor, Clifton D. Fuller, Eric Murray, David Majkszak, Nicole Dorio, Shlomo Koyfman, Neil Woody, Nikhil Joshi, Jacob G. Scott
medRxiv 2021.01.05.21249232; doi: https://doi.org/10.1101/2021.01.05.21249232
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
In Vivo Assessment of the Safety of Standard Fractionation Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma: An R-IDEAL Stage 1/2a First-in-Humans/Feasibility Demonstration of New Technology Implementation
Shireen Parsai, Richard Lei J. Qiu, Peng Qi, Geoffrey Sedor, Clifton D. Fuller, Eric Murray, David Majkszak, Nicole Dorio, Shlomo Koyfman, Neil Woody, Nikhil Joshi, Jacob G. Scott
medRxiv 2021.01.05.21249232; doi: https://doi.org/10.1101/2021.01.05.21249232

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (144)
  • Anesthesia (47)
  • Cardiovascular Medicine (419)
  • Dentistry and Oral Medicine (72)
  • Dermatology (49)
  • Emergency Medicine (147)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (174)
  • Epidemiology (4906)
  • Forensic Medicine (3)
  • Gastroenterology (185)
  • Genetic and Genomic Medicine (689)
  • Geriatric Medicine (72)
  • Health Economics (193)
  • Health Informatics (636)
  • Health Policy (322)
  • Health Systems and Quality Improvement (209)
  • Hematology (86)
  • HIV/AIDS (157)
  • Infectious Diseases (except HIV/AIDS) (5408)
  • Intensive Care and Critical Care Medicine (333)
  • Medical Education (96)
  • Medical Ethics (24)
  • Nephrology (77)
  • Neurology (692)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (128)
  • Occupational and Environmental Health (211)
  • Oncology (447)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (91)
  • Pain Medicine (37)
  • Palliative Medicine (18)
  • Pathology (131)
  • Pediatrics (201)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (88)
  • Psychiatry and Clinical Psychology (787)
  • Public and Global Health (1832)
  • Radiology and Imaging (328)
  • Rehabilitation Medicine and Physical Therapy (142)
  • Respiratory Medicine (257)
  • Rheumatology (87)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (63)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (38)